XTX Topco’s Arcus Biosciences RCUS Stock Holding History

XTX Topco’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,265	Closed	-$265K	–	4613
2026 Q1	$265K	Buy	+12,265	New	+$265K	﹤0.01%	2594
2025 Q3	–	Sell	-35,998	Closed	-$293K	–	3142
2025 Q2	$293K	Buy	+35,998	New	+$307K	0.01%	1448
2025 Q1	–	Sell	-18,434	Closed	-$274K	–	2977
2024 Q4	$274K	Buy	18,434 +7,239	+65%	+$118K	0.02%	1299
2024 Q3	$171K	Sell	11,195 -27,566	-71%	-$435K	0.01%	1491
2024 Q2	$590K	Buy	+38,761	New	+$626K	0.05%	580
2023 Q4	–	Sell	-21,970	Closed	-$394K	–	2036
2023 Q3	$394K	Buy	21,970 +5,507	+33%	+$111K	0.07%	549
2023 Q2	$334K	Buy	+16,463	New	+$313K	0.06%	638
2023 Q1	–	Sell	-10,800	Closed	-$223K	–	1595
2022 Q4	$223K	Buy	+10,800	New	+$297K	0.05%	774
2021 Q2	–	Sell	-9,648	Closed	-$271K	–	1042
2021 Q1	$271K	Buy	+9,648	New	+$336K	0.13%	327

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

XTX Topco's RCUS Position: Q2 2026 in Review

XTX Topco sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 12,265 shares — an estimated $265K sold.

XTX Topco first reported a position in RCUS in Q1 2021 and held it in 9 quarters. The position peaked at $590K in Q2 2024. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

XTX Topco reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 12,265 Arcus Biosciences shares in Q2 2026, an estimated $265K.
XTX Topco first reported a position in Arcus Biosciences in Q1 2021 and held it in 9 quarters.
XTX Topco's Arcus Biosciences position peaked at $590K in Q2 2024.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.